TX, UNITED STATES, December 24, 2025 / EINPresswire.com / -- Brown, LLC , a nationally recognized whistleblower and Medicaid and Medicare fraud law firm, announces a $41.5 million settlement with Pfizer Inc. and Tris Pharma, Inc. resolving claims brought under the Texas Health Care Program Fraud Prevention Act in the 71st Judicial District Court of Harrison County, Texas. The settlement addresses allegations that the companies improperly obtained Medicaid reimbursements for the ADHD medication Q

Vancouver, Canada, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel neuroplastogen-derived therapeutics to solve major under-treated health problems, today reflected on a year of significant momentum and progress in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD). Throughout 2025, Clearmind achieved cri

SYDNEY, Dec. 24, 2025 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce the acceptance of an abstract on the Co-PSMA (NCT06907641)[1] Investigator-Initiated Trial (IIT), led by Prof Louise Emmett at St Vincent's Hospital Sydney, for oral presentation at the upcoming European Association of Urolo

SHANGHAI, Dec. 24, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance from the U.S. Food and Drug Administration (FDA) for its self-developed anti-ST2 monoclonal antibody (R&D code: 9MW1911) to initiate a Phase IIa clinical study in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). As the first domestic anti-ST2 monoclonal antibody candidate to e

First and only approved option: YARTEMLEA ® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either

NOVATO, Calif.--(BUSINESS WIRE)--QT Imaging Holdings, Inc. (OTCQB: QTIH) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today confirms that it finalized the shipment of 40 scanners and met its revenue guidance of more than $18 million in 2025. “2025 was a transitional year for QT Imaging as we moved from early commercialization to scaled execution. We met our objectives and shipped scanners in

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, announced the appointment of Jeffrey R. Williams as Independent Director. “We are pleased to welcome Jeffrey to our Board of Directors for PharmaEssentia USA,” said Ko-Chung Lin, Ph.D., Founder and Chief Execut

The proportion of patients with serum luteinizing hormone (LH) suppression to < 4 mIU/mL at 60 minutes following a GnRHa stimulation test at Week 24 was 94%, and the results were statistically significant (P-value = 0.0005), which exceeded the pre-specified success criterion. Leuprolide mesylate 42mg injection (FP-001) was well tolerated in patients with Central Precocious Puberty (CPP) TAIPEI, Dec. 24, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced posit

Purchases reflect strong confidence in the scientific differentiation and commercial potential of ateganosine CHICAGO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that independent directors including Adelina Louie Ngar Yee and Stan V. Smith, Ph.D. purchased common stock and warrants in the recent private placement o

London: Sanofi will buy U.S. vaccines company Dynavax Technologies for around $2.2 billion (1.9 billion euros), the French drugmaker said on Wednesday, a deal that will give it access to an approved hepatitis B vaccine . Sanofi has made a string of acquisitions this year, as ‌it looks to diversify ‌growth beyond its blockbuster asthma drug Dupixent. It bought UK private biotech firm Vicebio for $1.5 billion in July shortly after finalising an up to $9.5 billion deal for U.S.-based ‌rare disease